Media City Scientific provides FRS, a chemically defined replacement for Fetal Bovine Serum (FBS) in cell culture. FRS ensures consistent cell behavior and experimental reproducibility, addressing the variability and contamination risks of animal-derived sera. This solution supports researchers in drug discovery and cell therapy development by offering a reliable and contaminant-free alternative.
Funding
Funding not disclosed
Founders
Product
Problem
The widespread use of Fetal Bovine Serum (FBS) in cell culture research presents significant challenges due to batch variability, potential for contamination, and ethical concerns. This variability impacts research reproducibility and hinders the translation of findings into clinical applications, particularly for cell therapies.
Solution
Media City Scientific offers FRS, a chemically defined and broad-spectrum replacement for FBS in cell culture applications. FRS provides enhanced consistency and reproducibility, addressing the inherent limitations of animal-derived sera. Its defined composition ensures reliable cell behavior and experimental outcomes, supporting robust scientific inquiry. This solution is designed to meet regulatory agency recommendations for reducing or replacing FBS in the manufacturing of human biological medicinal products. By utilizing FRS, researchers can improve the quality of their data and accelerate the development of advanced therapies.
Target Audience
Primary customers include academic research laboratories, biotechnology companies, and pharmaceutical organizations engaged in cell culture, drug discovery, and cell therapy development.
Features
- Chemically defined formulation for consistent performance and reproducibility.
- Broad-spectrum efficacy supporting a wide range of cell types.
- Contaminant-free composition, mitigating risks associated with animal-derived products.
- Cost-effective alternative to traditional FBS, reducing research expenditures.
- Supports regulatory compliance by offering a serum-free alternative.